title: Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
abstract: Neoplastic transformation is a multistep process in which gene products of specific regulatory pathways are involved at each stage. Identification of these overexpressed or mutated gene products provides an unprecedented opportunity to address the immune system against defined antigens and eliminate transformed cells. Mice transgenic for these oncogenes (e.g. HER-2/neu, a prototype of deregulated oncogenic protein kinase membrane receptors) are ideal experimental models for assessing the potential of active immunization. The demonstration that vaccines can cure HER-2/neu transplantable tumors, prevent their onset and delay the progression of preneoplastic lesions in mice at risk suggests that efficient immunological inhibition of HER-2/neu carcinogenesis can be achieved by specific vaccination. To further explore this issue, halting of tumor progression in the mammary glands of BALB-neuT mice with two immunization protocols in two laboratories has been studied independently by DNA microarray analysis. Combination of the two sets of results revealed a clear correlation between them when the tumor mass was titrated by transcription profiling. It was also clear that both protocols induced a strong, polyclonal antibody response and halted tumor growth at a condition very similar to that at which the vaccination began. Differences in the expression profiles were mainly related to the expression levels of a few chemokines and T-cell-specific genes that may be in some way correlated with the efficacy of the vaccination. Last, combination of the expression data with the protection results indicated that chronic vaccination is needed to maintain an active IFN-gamma-mediated response in the mammary gland.
authors.affiliation: Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, 40126, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Astolfi
authors.forename: Simona
authors.initials: S
authors.lastname: Rolla
authors.forename: Patrizia
authors.initials: P
authors.lastname: Nanni
authors.forename: Elena
authors.initials: E
authors.lastname: Quaglino
authors.forename: Carla
authors.initials: C
authors.lastname: De Giovanni
authors.forename: Manuela
authors.initials: M
authors.lastname: Iezzi
authors.forename: Piero
authors.initials: P
authors.lastname: Musiani
authors.forename: Guido
authors.initials: G
authors.lastname: Forni
authors.forename: Pier-Luigi
authors.initials: PL
authors.lastname: Lollini
authors.forename: Federica
authors.initials: F
authors.lastname: Cavallo
authors.forename: Raffaele A
authors.initials: RA
authors.lastname: Calogero
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D020869:Gene Expression Profiling; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D020411:Oligonucleotide Array Sequence Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases